Abstract：Objective To explore the effect of Buspirone on the treatment of negative symptoms of schizophrenia and its influence on cognitive function. Methods A total of 82 patients with negative symptoms of schizophrenia admitted to the Suzhou City Second People’s Hospital from February 2020 to February 2021 were selected. They were divided into control group and study group according to the random number table method. The control group was treated with low-dose Amisulpride, and the study group was treated with low-dose Amisulpride combined with Buspirone. Two groups of patients’ positive and negative symptom scale (PANSS) score, extrapyramidal side effects scale (RSESE) score, clinical efficacy, cognitive function (MMSE) score, serum prolactin (PRL), testosterone (T) levels, and adverse reactions were compared. Results After treatment, PANSS scores in both groups were lower than those before treatment, and the study group was lower than the control group (P ＜ 0.05); RSESE scores of the two groups were higher than before treatment, and the study group was higher than the control group (P ＜ 0.05); the clinical efficacy of the study group was better than that of the control group (P ＜ 0.05); MMSE scores of the two groups were higher than those before treatment, and the study group was higher than the control group (P ＜ 0.05); serum PRL and T levels in both groups were higher than those before treatment (P ＜ 0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Buspirone can improve clinical symptoms and cognitive function in patients with negative symptoms of schizophrenia, and is safe and reliable.
宋高峰 张成珍 姬祥利. 丁螺环酮治疗精神分裂症阴性症状的效果及对认知功能的影响[J]. 中国医药导报, 2022, 19(16): 161-164.
SONG Gaofeng ZHANG Chengzhen JI Xiangli. Effects of Buspirone in the treatment of negative symptoms of schizophrenia and its influence on cognitive function. 中国医药导报, 2022, 19(16): 161-164.
京公网安备 11010502046598号